By Vince Paolizzi, Peli BioThermal
Published in: Pharmaceutical online
Published on: May 11, 2022
Ultimately, the increasing complex protocols that attend modern clinical trials, coupled with the needs and preferences of the patients involved and the logistical challenges introduced by the pandemic, have made direct-to- and direct-from-patient shipping crucial tools for providers and trial sponsors alike. Data to date shows that DCTs boast a somewhat higher enrollment rate than traditional clinical trials; retention and compliance among patients is also frequently improved by offering home health services in place of a trial site. As the demand for temperature-sensitive samples and therapeutics continues to rise, facilitating these solutions through a supplier with the expertise and experience needed to grow alongside development is integral to advancing the biopharmaceutical industry’s impact and reach.